Development and Preclinical Characterization of an Fc-Optimized CD133 Antibody for Induction of NK Cell Reactivity Against Myeloid Leukemia

被引：2
|
作者：
Koerner, Samuel [1 ]
Leibold, Julia [1 ]
Grosse-Hovest, Ludger [2 ]
Buehring, Hans-Joerg [1 ]
Jung, Gundram [1 ]
Kanz, Lothar [3 ]
Salih, Helmut R. [1 ,4 ,5 ]
机构：
[1] Univ Tubingen, Tubingen, Germany
[2] SYNIMMUNE GmbH, Tubingen, Germany
[3] Univ Hosp Tuebingen, Tubingen, Germany
[4] German Canc Consortium DKTK, Heidelberg, Germany
[5] German Canc Res Ctr, Heidelberg, Germany
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
10.1182/blood.V124.21.2309.2309
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Monoclonal antibody CD133-2 (AC141) against hematopoietic stem cell antigen CD133 shows crossreactivity with cytokeratin 18
    Pötgens, AJG
    Schmitz, U
    Kaufmann, P
    Frank, HG
    JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 2002, 50 (08) : 1131 - 1134
  • [42] Preclinical validation of a novel CD133/CD3 bispecific T -cell engager (BiTE) antibody to target patient -derived glioblastoma cells
    Vora, Parvez
    Venugopal, Chitra
    Adams, Jarrett
    Pan, James
    Chokshi, Chirayu
    Qazi, Maleeha
    Subapanditha, Minomi
    Singh, Mohini
    Bakhshinyan, David
    Bezverbnaya, Ksenia
    McFarlane, Nicole
    Bramson, Jonathan
    Sidhu, Sachdev
    Moffat, Jason
    Singh, Sheila
    CANCER RESEARCH, 2016, 76
  • [43] Development and Evaluation of NK-CD123 CAR Against High Risk Acute Myeloid Leukemia
    Sinha, Chandrima
    Seth, Aman
    Kahali, Bhaskar
    Cunningham, Lea
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (03) : S212 - S212
  • [44] CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells
    Baessler, Tina
    Charton, Jean Enno
    Schmiedel, Benjamin Joachim
    Gruenebach, Frank
    Krusch, Matthias
    Wacker, Alexander
    Rammensee, Hans-Georg
    Salih, Helmut Rainer
    BLOOD, 2010, 115 (15) : 3058 - 3069
  • [45] Potentiation of targeted and activated NK cells for therapy of acute myeloid leukemia with bispecific antibody to CD33 and CD16 (Fc gamma RIII)
    Zhong, RK
    Shultz, LD
    Chen, J
    Jiang, B
    Whiteside, TL
    Ball, ED
    BLOOD, 1995, 86 (10) : 3143 - 3143
  • [46] Generation and Preclinical Characterization of an NKp80-Fc Fusion Protein for Redirected Cytolysis of Natural Killer (NK) Cells against Leukemia
    Deng, Gang
    Zheng, Xiaodong
    Zhou, Jing
    Wei, Haiming
    Tian, Zhigang
    Sun, Rui
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2015, 290 (37) : 22474 - 22484
  • [47] Induction of NK Cell Reactivity Against AML Cells by Fc-Engineered RANK-Ig Fusion Proteins.
    Nuebling, Tina
    Schmiedel, Benjamin J.
    Azuma, Miyuki
    Schneider, Pascal
    Grosse-Hovest, Ludger
    Kanz, Lothar
    Salih, Helmut R.
    BLOOD, 2012, 120 (21)
  • [48] Monitoring of ADCC with a Fc-optimized CD19 antibody in post-transplant MRD treatment of paediatric patients with refractory B-lineage acute lymphoblastic leukemia
    Seidel, U. J. E.
    Grosse-Hovest, L.
    Schlegel, P.
    Handgretinger, R.
    Jung, G.
    Aulwurm, S.
    Hofmann, M.
    Pyz, E.
    Rammensee, H. G.
    Lang, P.
    IMMUNOLOGY, 2012, 137 : 716 - 716
  • [49] Differential Effects of the BCR-ABL-Inhibitors Imatinib, Nilotinib and Dasatinib on NK Cell Reactivity against Chronic Myeloid Leukemia (CML)
    Krusch, Matthias
    Salih, Julia
    Kanz, Lothar
    Salih, Helmut R.
    BLOOD, 2008, 112 (11) : 1098 - 1098
  • [50] Preclinical characterization of MT114, a novel CD33/CD3-bispecific BiTE antibody for the treatment of acute myeloid leukemia (AML)
    Henn, Anja
    Friedrich, Matthias
    Kischel, Roman
    Lutterbuese, Ralf
    Schneider, Katja
    Mueller, Peter
    Baeuerle, Patrick A.
    Raum, Tobias
    Kufer, Peter
    Rattel, Benno
    CANCER RESEARCH, 2012, 72
12345